Drug Search Results

Traxoprodil

Alternative Names: traxoprodil
Latest Update: 2023-05-25
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NMDA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Traxoprodil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success

Recent News Events

Date	Type	Title
05/25/2023	PubMed	Binding Affinity and Mechanisms of Potential Antidepressants Targeting Human NMDA Receptors.
03/01/2023	PubMed	Antidepressant-like effect of CP-101,606: Evidence of mTOR pathway activation.
02/10/2023	PubMed	Traxoprodil Produces Antidepressant-Like Behaviors in Chronic Unpredictable Mild Stress Mice through BDNF/ERK/CREB and AKT/FOXO/Bim Signaling Pathway.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions